COHANCE vs INDOCO: Stock Comparison

COHANCE LIFESCIENCES vs INDOCO REMEDIESUpdated 4 Sept 26, 4:08 PM ISTNSE & company filings

COHANCE LIFESCIENCES is the larger company by market capitalisation. COHANCE LIFESCIENCES shows a lower P/E, a higher ROE and lower leverage, while INDOCO REMEDIES shows faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

COHANCE leads 6; INDOCO leads 5 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

COHANCEINDOCO

Valuation lens

What price are you paying?

Market CapContext only
₹17,460 Cr
₹2,421 Cr
P/E RatioCOHANCE has the lower reading
165.47x
445.9x
P/B RatioINDOCO has the lower reading
4.5x
2.67x
EPSINDOCO has the higher reading
₹0.04
₹7.04
Book ValueContext only
₹105.44
₹100.98
Dividend YieldSame reading
0%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
COHANCE is the larger company
₹17,460 Cr vs ₹2,421 Cr
P/E Ratio
COHANCE has a lower P/E
165.47x vs 445.9x
P/B Ratio
INDOCO has a lower P/B
2.67x vs 4.5x
EPS
INDOCO has higher earnings per share
₹7.04 vs ₹0.04
Revenue Growth (TTM YoY)
INDOCO has faster revenue growth
21.9% vs -26.3%
EPS Growth (TTM YoY)
INDOCO has faster EPS growth
0% vs -89%
Qtr Sales Growth
INDOCO has stronger quarterly sales growth
14.31% vs -14.77%
Qtr Profit Growth
COHANCE has stronger quarterly profit growth
103.12% vs -20.51%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricCOHANCEINDOCO
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricCOHANCEINDOCO
Live Price₹456.6₹262.51
Day Change-0.92%-3.69%
Volume5.73 L3.69 L
52-Week High₹1,038.9₹332.2
52-Week Low₹266.7₹162.19
Distance from 52W High-56.05%-20.98%

Valuation

MetricCOHANCEINDOCO
Market Cap₹17,460 Cr₹2,421 Cr
P/E Ratio165.47x445.9x
P/B Ratio4.5x2.67x
EPS₹0.04₹7.04
Book Value₹105.44₹100.98
Dividend Yield0%0%

Growth

MetricCOHANCEINDOCO
Revenue Growth (TTM YoY)-26.3%21.9%
EPS Growth (TTM YoY)-89%0%
Qtr Sales Growth-14.77%14.31%
Qtr Profit Growth103.12%-20.51%

Profitability & Leverage

MetricCOHANCEINDOCO
ROE3.72%-0.51%
ROCE4.26%4.26%
Net Margin7.9%-5.31%
Operating Margin10.77%4.57%
Debt to Equity0.04x0.64x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricCOHANCEINDOCO
Promoter Holding0%58.86%
FII Holding6.5% 0.91 pp1.27% 0.33 pp
DII Holding20.09% 1.7 pp17.68% 0.47 pp
Public Holding15.92% 0.8 pp22.04% 0.14 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: COHANCE LIFESCIENCES and INDOCO REMEDIES.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.